Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $41.2 million.

  • Conmed's Free Cash Flow rose 490.1% to $41.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $150.9 million, marking a year-over-year decrease of 195.02%. This contributed to the annual value of $150.9 million for FY2025, which is 195.02% down from last year.
  • Per Conmed's latest filing, its Free Cash Flow stood at $41.2 million for Q4 2025, which was up 490.1% from $48.5 million recorded in Q3 2025.
  • Over the past 5 years, Conmed's Free Cash Flow peaked at $51.5 million during Q4 2023, and registered a low of -$17.3 million during Q4 2022.
  • Its 5-year average for Free Cash Flow is $26.0 million, with a median of $28.8 million in 2021.
  • In the last 5 years, Conmed's Free Cash Flow skyrocketed by 204676.34% in 2021 and then tumbled by 15645.65% in 2022.
  • Quarter analysis of 5 years shows Conmed's Free Cash Flow stood at $30.6 million in 2021, then plummeted by 156.46% to -$17.3 million in 2022, then skyrocketed by 398.37% to $51.5 million in 2023, then fell by 23.75% to $39.3 million in 2024, then rose by 4.9% to $41.2 million in 2025.
  • Its last three reported values are $41.2 million in Q4 2025, $48.5 million for Q3 2025, and $23.4 million during Q2 2025.